Clinical OMICS

NOV-DEC 2018

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: https://clinicalomics.epubxp.com/i/1040438

Contents of this Issue

Navigation

Page 38 of 51

www.clinicalomics.com November/December 2018 Clinical OMICs 37 genomic side, Konica Minolta from the nanotechnology side, and Invicro predominantly from the radiology side," Bloom, who is also CMO for Invicro and Ambry Genetics, told Clinical OMICs. "As a result of the companies coming together, this allows us to go to pharma with an agnostic biomarker strategy. We bring everything to the table from a science standpoint, so when we sit and talk to a pharma company, we don't have a vested interest one way or another who wins. We get you the best solution for what your prob- lem is. That's very appealing to pharma." Konica Minolta's ability to integrate radiology, pathol- ogy, and genomic information, he said, will serve over time as a differentiator. Through Ambry, Konica Minolta offers genetic testing solutions for inherited and non-inherited diseases, as well as for numerous clinical specialties that include oncology, cardiology, pulmonology, neurology, and general genetics. Pursuing Opportunities Across all those areas, Konica Minolta said, it plans to pur- sue opportunities for new germline and somatic tests fol- lowing a recent review of its testing menu. The company reasons that biopharmas focused on treating rare genetic disorders, or developing precision cancer treatments like PARP inhibitors, will want to access Ambry's comprehen- sive testing to help them identify patients who may benefit from new therapies. Through Boston-based Invicro, Konica Minolta offers pharmaceutical development support services from ear- ly-phase discovery through late-phase clinical trials to approximately 140 businesses, primarily biopharmas. It specializes in searching for and establishing central ner- vous system biomarkers for cancer and Alzheimer 's disease using its VivoQuant image data visualization and analysis software and iPACS data management platform. Since its founding 10 years ago, Invicro has evolved into a service provider specializing on quantitative imaging biomarker assays. For most of its history, Invicro focused on discov- ery-phase imaging, but expanded into clinical-phase research in 2016 when it acquired Molecular Neuroui- maging, along with additional acquisitions last year of Imanova and CORE Clinical. "The combination of Konica Minolta's robust precision medicine platform with Invicro's strong track record with the world's top 20 pharmaceutical and biotech companies, as well as leading research universities, will accelerate our mission by a couple of years to go beyond just the medi- cal imaging and software sectors," Invicro Co-Founder and CEO Jack Hoppin, Ph.D., said in the company's annual Inte- grated Report 2018. (continued on next page) Konica-Minolta's push into genomic and precision medicine is centered around two acquisitions from 2007: contract research organization Invicro, and Ambry Genetics (pictured).

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - NOV-DEC 2018